Clopidogrel RPG may be available in the countries listed below.
Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Clopidogrel RPG in the following countries:
International Drug Name Search
Azitromycine Sandoz may be available in the countries listed below.
Azithromycin is reported as an ingredient of Azitromycine Sandoz in the following countries:
International Drug Name Search
Dog Net may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Permethrin is reported as an ingredient of Dog Net in the following countries:
International Drug Name Search
Propranolol Alpharma ApS may be available in the countries listed below.
Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Propranolol Alpharma ApS in the following countries:
International Drug Name Search
Klotrimazol may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Klotrimazol in the following countries:
International Drug Name Search
Atonin O may be available in the countries listed below.
Oxytocin is reported as an ingredient of Atonin O in the following countries:
International Drug Name Search
In the US, Rimso-50 (dimethyl sulfoxide systemic) is a member of the drug class miscellaneous genitourinary tract agents and is used to treat Interstitial Cystitis.
US matches:
Dimethyl Sulfoxide is reported as an ingredient of Rimso-50 in the following countries:
International Drug Name Search
Ivorat may be available in the countries listed below.
Bemiparin Sodium is reported as an ingredient of Ivorat in the following countries:
International Drug Name Search
Cromal may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cromal in the following countries:
International Drug Name Search
Doxorubicin Pfizer may be available in the countries listed below.
Doxorubicin hydrochloride (a derivative of Doxorubicin) is reported as an ingredient of Doxorubicin Pfizer in the following countries:
International Drug Name Search
Treating mild to moderate aches and pains associated with headache, muscle and joint soreness, backache, menstrual cramps, colds and flu, sinusitis, toothache, and minor pain from arthritis, and to reduce fever. It may also be used for other conditions as determined by your doctor.
Rid-A-Pain Compound is an analgesic and antipyretic combination. It works by blocking substances in the body that cause fever, pain, and inflammation.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Rid-A-Pain Compound. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Rid-A-Pain Compound. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Rid-A-Pain Compound may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Rid-A-Pain Compound as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Rid-A-Pain Compound.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Anxiety or nervousness; dizziness; drowsiness; heartburn; nausea; upset stomach; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or black stools; confusion; dark urine or pale stools; decreased urination; diarrhea; difficulty swallowing; dizziness; hearing loss; hoarseness; persistent sore throat or other signs of infection; ringing in the ears; severe or persistent vomiting; severe stomach pain; unusual bruising or bleeding; unusual tiredness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Rid-A-Pain Compound side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include abnormal behavior; dark urine; excessive sweating; extreme tiredness; fast or deep breathing; loss of consciousness; ringing in the ears; stomach pain; vomiting.
Store Rid-A-Pain Compound at room temperature, 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Rid-A-Pain Compound out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Rid-A-Pain Compound. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Zolon may be available in the countries listed below.
Zopiclone is reported as an ingredient of Zolon in the following countries:
International Drug Name Search
RYNA®-12 is an antihistamine/nasal decongestant combination available for oral administration as Tablets and as Suspension. Each tablet contains:
Phenylephrine Tannate 25 mg
Pyrilamine Tannate 60 mg
Other ingredients: corn starch, dibasic calcium phosphate, magnesium stearate, methylcellulose, polygalacturonic acid, talc.
Each 5 mL (one teaspoonful) of the pink-colored, natural strawberry-artificial currant flavored Suspension contains:
Phenylephrine Tannate 5 mg
Pyrilamine Tannate 30 mg
Other ingredients: benzoic acid, FD&C Red No. 3, flavors (natural and artificial), glycerin, kaolin, magnesium aluminum silicate, methylparaben, pectin, purified water, saccharin sodium, sucrose.
RYNA®-12 combines the sympathomimetic decongestant effect of phenylephrine with the antihistaminic action of pyrilamine.
RYNA®-12 is indicated for symptomatic relief of the coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease.
RYNA®-12 is contraindicated for newborns, nursing mothers and patients sensitive to any of the ingredients or related compounds.
Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma or prostatic hypertrophy. Use with caution or avoid use in patients taking monoamine oxidase (MAO) inhibitors, or within 14 days of stopping such treatment. These products contain an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).
General: Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation.
Information for patients: Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery while using these products. Patients should be warned not to use these products if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product.
Drug interactions: MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents.
Carcinogenesis, mutagenesis, impairment of fertility: No long-term animal studies have been performed with RYNA®-12.
Pregnancy: Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with RYNA®-12. It is also not known whether RYNA®-12 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RYNA®-12 should be given to a pregnant woman only if clearly needed.
Nursing mothers: RYNA®-12 should not be administered to a nursing woman.
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adverse effects associated with RYNA®-12 at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare.
Signs & symptoms: May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent.
Treatment: Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered.
Administer the recommended dose every 12 hours.
RYNA®-12 Tablets: Adults — 1 or 2 tablets.
Children 6 to 11 years — 1/2 or 1 tablet. Ryna-12 S ® Suspension: Children over six years of age — 5 to 10 mL (1 to 2 teaspoonfuls); Children two to six years of age — 2.5 to 5 mL (1/2 to 1 teaspoonful); Children under two years of age — Titrate dose individually.
RYNA®-12 Tablets (phenylephrine tannate 25 mg, and pyrilamine tannate 60 mg): buff-colored, capsule-shaped, scored on one side and imprinted WALLACE 673 on the other side. The tablets are available in bottles of 100 (NDC 0037-0673-10).
Ryna-12 S® Suspension (phenylephrine tannate 5 mg, and pyrilamine tannate 30 mg per 5 mL) in 4 fl oz unit of use container with a 10 mL graduated oral syringe and fitment (NDC 0037-0655-04, labeled Ryna-12 S®).
Storage: RYNA®-12 Tablets — Store at controlled room temperature 20°-25°C (68°-77°F).
Ryna-12 S® Suspension — Store at controlled room temperature 20°-25°C (68°-77°F).
U.S. Patent 6,287,597
Produced under license from
JFC Technologies
Bound Brook, NJ, U.S.A.
U.S. Patents 5,599,846; 5,663,415
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
MEDA
PHARMACEUTICALS®
Meda Pharmaceuticals Inc.
Somerset, New Jersey 08873-4120
Printed in U.S.A. Rev. 3/09
NDC 0037-0655-04
4 fl oz (118 mL)
Ryna-12 S®
SUSPENSION
Each 5 mL (teaspoonful)
contains:
Phenylephrine Tannate 5 mg
Pyrilamine Tannate 30 mg
U.S. Patent 6,287,597
Rx Only
SHAKE WELL
LB-065504-04 Rev. 10/03
Usual Dosage:
See full prescribing information on bottom of tray.
See enclosed patient instructions for use of fitment and syringe.
Store at controlled room temperature 20°-25°C (68°-77°F).
Produced under license from
JFC Technologies
Bound Brook, NJ, U.S.A.
U.S. Patents 5,599,846; 5,663,415
MedPointe Pharmaceuticals
MedPointe Healthcare Inc.
Somerset, New Jersey 08873
NDC 0037-0673-10
100 Tablets
RYNA®-12
Each tablet contains:
Phenylephrine Tannate 25 mg
Pyrilamine Tannate 60 mg
U.S. Patent 6,287,597
Rx Only
LB-067310-02 Rev. 10/03
USUAL DOSE: See package insert.
Store at controlled room tempera-
ture 20°-25°C (68°-77°F).
Protect from moisture.
Dispense in a tight container.
Produced under license from
JFC Technologies
Bound Brook, NJ, U.S.A.
U.S. Patents 5,599,846; 5,663,415
MedPointe Pharmaceuticals
MedPointe Healthcare Inc.
Somerset, New Jersey 08873
| RYNA -12 S phenylephrine tannate and pyrilamine tannate suspension | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| UNAPPROVED DRUG OTHER | 09/01/1999 | 05/31/2011 | |
| RYNA -12 phenylephrine tannate and pyrilamine tannate tablet | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| UNAPPROVED DRUG OTHER | 09/01/2002 | 05/31/2012 | |
| Labeler - Meda Pharmaceuticals Inc. (051229602) |
Ambrobene retard may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambrobene retard in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Coma Induction. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Gyno-Travogen may be available in the countries listed below.
Isoconazole nitrate (a derivative of Isoconazole) is reported as an ingredient of Gyno-Travogen in the following countries:
International Drug Name Search
